Carlsbad, CA 7/25/12—Life Technologies has acquired Pinpoint Genomics, a developer of an early-stage non-small cell lung cancer test for the identification of patients at risk for late-stage disease. “We see an opportunity in lung cancer to change the treatment paradigm with more effective diagnostics,” stated Gregory T. Lucier, chairman and CEO of Life Technologies. “As Life Technologies moves further into the diagnostics space, we will focus on tests that have strong clinical utility where there is a large unmet need.” Pinpoint Genomics’ quantitative PCR lab-developed test, which measures expression of a 14-gene panel, has been validated in large-scale, independent studies. The company expects this acquisition and the acquisition of Navigenics (see above) to be $0.02 dilutive to earnings in 2012, $0.5 dilutive in 2013 and accretive thereafter. In addition to offering the test on its platform in the Pinpoint Genomics lab, Life Technologies will pursue in vitro diagnostic certification outside the US.